MétaCan
Menu
Back to cohort
Record W4395670346 · doi:10.1111/bdi.13435

Early intervention, relapse prevention, and neuroprogression in bipolar disorder: The evidence matters

2024· editorial· en· W4395670346 on OpenAlexaff
Lakshmi N. Yatham, Ayal Schaffer, Lars Vedel Kessing, Kamilla Woznica Miskowiak, Flávio Kapczinski, Eduard Vieta, Robert M. Post, Michael Berk

Bibliographic record

VenueBipolar Disorders · 2024
Typeeditorial
Languageen
FieldMedicine
TopicBipolar Disorder and Treatment
Canadian institutionsMcMaster UniversityUniversity of TorontoSunnybrook Health Science CentreHealth Sciences CentreUniversity of British Columbia
Fundersnot available
KeywordsBipolar disorderRelapse preventionIntervention (counseling)PsychiatryPsychologyPsychotherapistClinical psychologyMedicineMood

Abstract

fetched live from OpenAlex

Yatham LN: reports consultant/speaker fees from Alkermes, Allergan (currently Abbvie) Dainippon Sumitomo Pharma, Gedeon Richter, GSK, Intracellular Therapies, Merck, Sanofi, and Sunovion, and grants from Allergan (now AbbVie), CIHR, and Dainippon Sumitomo, outside the submitted work, over the last 3 years. Schaffer A has received consultant/speaker fees from Allergan/Abbvie, GSK, Lundbeck, Otsuka in the past 3 years. Kessing LV has been a consultant for Teva and Lundbec during the last 3 years. Miskowiak KW reports consultancy fees from Lundbeck, Angelini, Gedeon Richter, and Janssen-Cilag in the past 3 years. Kapczinski F received grants or participated in the board or as speaker for the following entities: Johnson & Johnson, Daiichi Sankyo, Ache, and Janssen. Vieta E has received grants and served as consultant, advisor or CME speaker for the following entities: AB-Biotics, AbbVie, Adamed, Angelini, Biogen, Biohaven, Boehringer-Ingelheim, Celon Pharma, Compass, Dainippon Sumitomo Pharma, Ethypharm, Ferrer, Gedeon Richter, GH Research, Glaxo-Smith Kline, HMNC, Idorsia, Johnson & Johnson, Lundbeck, Medincell, Merck, Newron, Novartis, Orion Corporation, Organon, Otsuka, Roche, Rovi, Sage, Sanofi-Aventis, Sunovion, Takeda, and Viatris, outside the submitted work. Post RM: Speaker for Sunovion and Abbvie. Berk M: Grant/Research Support: MRFF, NHMRC, Congressionally Directed Medical Research Programs (CDMRP) USA, AEDRTC Australian Eating Disorders Research and Translation Centre, Patient-Centered Outcomes Research Institute (PCORI), Baszucki Brain Research Fund, Danmarks Frie Forskningsfond. Psykiatrisk Center Kobenhavn, Stanley Medical Research Institute, Victorian Government Department of Jobs, Precincts and Regions, Wellcome Trust, Victorian Medical Research Acceleration Fund, Controversias Psiquiatria Barcelona, CRE, Victorian COVID-19 Research Fund, Consultancies: Lundbeck, Sandoz, Servier, Medisquire, HealthEd, ANZJP, EPA, Janssen, Medplan, RANZCP, Abbott India, ASCP, International Society of Bipolar Disorder, Precision Psychiatry, Penn State College of Medicine, Shanghai Mental Health Centre. (Last 3 years)—all unrelated to this work. Data sharing not applicable to this article as no datasets were generated or analysed during the current study.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.006
metaresearch head score (Gemma)0.024
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Editorial · Consensus signal: none
Teacher disagreement score0.010
Threshold uncertainty score0.033

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0060.024
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0030.003
Bibliometrics0.0010.001
Science and technology studies0.0000.001
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0100.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.009
GPT teacher head0.287
Teacher spread0.277 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreEditorial

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations8
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueBipolar DisordersSame topicBipolar Disorder and TreatmentFrench-language works237,207